About This Source - Bloomberg QuickTake: Now
Bloomberg L.P. is a privately held financial, software, data, and media company headquartered in Midtown Manhattan, New York City.
It was founded by Michael Bloomberg in 1981, with the help of Thomas Secunda, Duncan MacMillan, Charles Zegar, and a 12% ownership investment by Merrill Lynch.
Recent from Bloomberg QuickTake: Now:
Bloomberg Quicktake: Now published this video item, entitled “Covid-19: How Concerning is India’s ‘Double-Mutant’ Variant?” – below is their description.
As coronavirus infections surge by more than 300,000 cases for 15 straight days, pushing India’s tally past 21 million, the country’s limited ability to track new mutations emerging from its outbreak is a growing concern for scientists.
The good news is that the vaccines work against a new virus strain circulating in India that’s spread to several other countries.
The bad news is it won’t be only the new version of the pathogen to emerge from an outbreak of this scale, underscoring the urgency of mapping other possible variants that may be currently racing through India’s tightly-packed population of 1.4 billion people.
Mutations occur when the virus replicates, and India’s unprecedented surge is driving new cases to global records, even as richer economies like the U.S. and Israel re-open quickly. Fearing an influx of infections and mindful of B.1.617, Singapore, the U.K. and Tanzania are among countries that have curbed travel to and from India.
The India strain has been called a double mutant because of the presence of two changes in the virus’s genome, called E484Q and L452R. Both affect a portion of the spike protein, called the receptor binding domain, that’s key to the virus entering cells.
Some researchers estimate that the B.1.617 variant is as transmissible as the B.1.1.7 variant that emerged in the U.K., thought to be as much as 70% more transmissible than earlier versions of the virus.
Yet initial analyses indicate that the India version, now classified a variant of interest by the World Health Organization, poses a limited threat and doesn’t appear to be more dangerous.
Covaxin, the inactivated-virus vaccine being made by India’s Bharat Biotech International Ltd., and AstraZeneca Plc’s vaccine, called Covishield in India, are effective against the strain in preventing serious illness, said Rakesh Mishra, director of the Centre for Cellular and Molecular Biology in Hyderabad, one of the labs analyzing virus samples. Data is still being gathered about the response to Russia’s Sputnik V vaccine, Mishra said, but it’s likely to be effective.
BioNTech CEO Ugur Sahin said he was confident the mRNA shot it’s making with partner Pfizer Inc. would work against the India mutant though testing is still ongoing. “The Indian variant has the same mutation that we’ve already investigated and against which our vaccine was also effective,” he said last week.
Singapore has also seen vaccines hold up well to prevent serious illness, said Kenneth Mak, director of medical services in city-state’s health ministry. But “vaccination does not prevent you from getting infected 100%,” he said in a Tuesday briefing.
Ravindra Gupta’s team at the University of Cambridge recently studied the two mutations that appear on the receptor binding domain of the India variant’s spike protein. The team tested viruses made to simulate the variant against serum from nine people who had already received a single dose of the BioNTech-Pfizer vaccine.
“We wanted to know whether this double mutant really is a double whammy,” said Gupta, a professor of clinical microbiology at Cambridge’s Institute for Therapeutic Immunology and Infectious Diseases. What they found was that while each of the mutations could partly evade neutralizing antibodies, the two mutations didn’t combine to create an even greater ability to evade immune protection.
“They don’t combine to make a super mutant,” Gupta said. “It kind of debunks this view that this double mutant is doubly evading neutralizing antibodies.”
While the findings ease concerns around B.1.617, researchers are turning to the next set of variants as India’s outbreak continues to rage. Genomic surveillance can provide crucial information on the new forms of this shape-shifting virus — critical in preventing subsequent waves and developing the next generation of vaccines.
“Mass surveillance of genome sequencing, just keep mapping out the virus from positive Covid samples across the country, that’s the only way you can map the next set of mutants,” says Bloomberg reporter Bhuma Shrivastava.Bloomberg Quicktake: Now YouTube Channel
Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.
In This Story: AstraZeneca
AstraZeneca plc/AB (LON: AZN) is a British-Swedish multinational pharmaceutical and biopharmaceutical company with its headquarters in Cambridge, United Kingdom and Södertälje, Sweden. Its R&D is concentrated in Cambridge in United Kingdom, Södertälje in Sweden, and Maryland and Toronto in North America.
3 Recent Items: AstraZeneca
In This Story: BioNTech
BioNTech SE (NASDAQ: BNTX) is a German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases.
5 Recent Items: BioNTech
In This Story: COVID-19
Covid-19 is the official WHO name given to the novel coronavirus which broke out in late 2019 and began to spread in the early months of 2020.
Symptoms of coronavirus
The main symptoms of coronavirus are:
- a persistent new cough (non productive, dry)
- a high temperature (e.g. head feels warm to the touch)
- shortness of breath (if this is abnormal for the individual, or increased)
Latest News about Covid-19
Below are stories from around the globe related to the 2020 outbreak of novel Coronavirus – since the WHO gave the Covid-19 naming. Most recent items are posted nearest the top.
5 Recent Items: COVID-19
In This Story: India
It has an exceptionally diverse population, with Hindus, Muslims, Christians, Sikhs, Buddhists, Jains and other religions speaking over 21 recognised languages.
2 Recent Items: India
In This Story: Israel
Israel, a Middle Eastern country on the Mediterranean Sea, is regarded by Jews, Christians and Muslims as the biblical Holy Land. Its most sacred sites are in Jerusalem. Within its Old City, the Temple Mount complex includes the Dome of the Rock shrine, the historic Western Wall, Al-Aqsa Mosque and the Church of the Holy Sepulchre. Israel’s financial hub, Tel Aviv, is known for its Bauhaus architecture and beaches.
2 Recent Items: Israel
In This Story: Pfizer
Pfizer Inc. (NYSE: PFE) is an American multinational pharmaceutical corporation headquartered in New York City. In 2012, it was one of the world’s largest pharmaceutical companies and ranked 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.
5 Recent Items: Pfizer
In This Story: Singapore
The country’s territory is composed of one main island, 63 satellite islands and islets, and one outlying islet, the combined area of which has increased by 25% since the country’s independence as a result of extensive land reclamation projects. It has the second greatest population density in the world. The country has almost 5.7 million residents, 61% (3.4 million) of whom are Singaporean citizens. There are four official languages of Singapore: English, Malay, Chinese, and Tamil; with English being the lingua franca.
2 Recent Items: Singapore
In This Story: Sputnik V
Gam-COVID-Vac, trade-named Sputnik V, is a COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology, and registered on 11 August 2020 by the Russian Ministry of Health. It has been approved for distribution in Russia.
The phase III trial for Gam-COVID-Vac was registered on 28 August 2020, and is a randomised, double-blind, placebo-controlled, multi-centre clinical trial involving 40,000 volunteers. The phase III trial is scheduled to run until May 2021.
On 5 December 2020, Russia began mass vaccinations in Moscow, with 70 clinics inoculating those most at risk from the virus. Health workers and teachers were said to have priority in the first mass immunisation programme. People who had received injections in the last 30 days or had respiratory diseases in the previous two weeks were excluded, as well as those with certain chronic illnesses, and pregnant and breastfeeding women.